BioCryst Pharmaceuticals, Inc. Appoints Babar Ghias Chief Financial Officer

Published: 2025-07-07 08:21:05 ET BCRX

Published on 07/07/2025 at 08:21

BioCryst Pharmaceuticals, Inc. announced the appointment of Babar Ghias as chief financial officer (CFO). Mr. Ghias joins BioCryst from AvenCell Therapeutics, a clinical-stage CAR-T company focused on hematologic malignancies, where he served as CFO since 2022. Previously, Mr. Ghias was executive vice president of investments and portfolio management at Paragon Biosciences, a global biotech development firm.

He also served as chief financial and operating officer for several Paragon portfolio companies. At Paragon, he launched four biotechnology companies focused on rare diseases from early clinical to successful commercial launch. From 2014 to 2017, he served as CFO and head of corporate development at Marathon Pharmaceuticals, a specialty rare disease company, where he prepared the company for a commercial launch and led the successful sale of the firm.

Mr. Ghias has raised over $1 billion in capital for the companies he has been involved with. Earlier in his career, for over a decade, he was an investment banker who served as a senior member of the mergers and acquisitions team at Credit Suisse, providing strategic advice to clients and boards of directors in the healthcare and life sciences industries and successfully closing over $80 billion in transactions. Mr. Ghias earned his M.B.A. with honors from Washington University in St.

Louis and holds a B.S. in economics from Lahore University of Management Sciences in Pakistan.